June 1, 2024Journal of Clinical Oncology

A real-world picture of patients with a new diagnosis of acute myeloid leukemia in Italy.

View Full Paper

Ask AI

Bookmark

Authors

IEImmacolata EspositoUnited States Food and Drug Administration GRGiulia RonconiFondazione Roma LDLetizia DondiFondazione Roma

Discussion

Member takes

Implication

Observational study shows improved two-year overall survival with antineoplastic treatment in acute myeloid leukemia, suggesting broader therapy access benefits high-risk groups.

Key Points

Antineoplastic treatment significantly extends overall survival among patients newly diagnosed with acute myeloid leukemia, whereas older individuals remain untreated.
Two-year overall survival reached 97% in treated patients compared with 65% in untreated cohorts, and intensive chemotherapy conferred distinct advantages.
Highlights from administrative healthcare data suggest chemotherapy and allogeneic stem cell transplantation increase survival, though older adults face exclusion.

Cite This Study

Esposito et al. (2024) studied this question.

synapsesocial.com/papers/68e671c0b6db6435875fbfb8 https://doi.org/10.1200/jco.2024.42.16_suppl.6520

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows improved two-year overall survival with antineoplastic treatment in acute myeloid leukemia, suggesting broader therapy access benefits high-risk groups.

A real-world picture of patients with a new diagnosis of acute myeloid leukemia in Italy.

Discussion

Member takes

Implication

Key Points

Cite This Study

A real-world picture of patients with a new diagnosis of acute myeloid leukemia in Italy.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider